 |
124 Diseases |  |
24 Trials |
|
24 Trials |  |
2082 News |  |
| «12...14151617181920212223242526» |
- | Enrollment open, Trial initiation date: WARRIOR: Women's IschemiA TRial to Reduce Events In Non-ObstRuctive CAD (clinicaltrials.gov) - Feb 14, 2018
P4, N=4422, Recruiting, Sponsor: University of Florida
Not yet recruiting --> Recruiting | Initiation date: Feb 2018 --> Feb 2018
- | lisinopril / Generic mfg.
New P2 trial: A Pilot Study: Preventing Adverse Remodelling Following Pacemaker Implantation (clinicaltrials.gov) - Feb 6, 2018
P2, N=75, Not yet recruiting, Sponsor: University of Leeds
- | New P4 trial: WARRIOR: Women's IschemiA TRial to Reduce Events In Non-ObstRuctive CAD (clinicaltrials.gov) - Jan 30, 2018
P4, N=4422, Not yet recruiting, Sponsor: University of Florida
- | lisinopril / Generic mfg.
New P4 trial: Prophylactic Lisinopril to Prevent Anthracycline Cardiomyopathy. (clinicaltrials.gov) - Jan 8, 2018
P4, N=200, Not yet recruiting, Sponsor: Genesys Regional Medical Center
- | pravastatin / Generic mfg., lisinopril / Generic mfg.
Journal: Pharmacologic Prevention of Incident Atrial Fibrillation: Long-Term Results From the ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial). (Pubmed Central) - Dec 21, 2017
P3
Not yet recruiting --> Recruiting | Initiation date: Feb 2018 --> Feb 2018 Compared with chlorthalidone, treatment with lisinopril is not associated with a meaningful reduction in incident AF or AFL among older adults with a history of hypertension.
- | lisinopril / Generic mfg.
Trial initiation date: Optimal Management of HIV Infected Adults at Risk for Kidney Complications in Nigeria (clinicaltrials.gov) - Dec 14, 2017
P2, N=200, Not yet recruiting, Sponsor: Vanderbilt University Medical Center
Compared with chlorthalidone, treatment with lisinopril is not associated with a meaningful reduction in incident AF or AFL among older adults with a history of hypertension. Initiation date: Nov 2017 --> Feb 2018
- | atorvastatin / Generic mfg., lisinopril / Generic mfg.
Trial primary completion date, Surgery: OPTMIZE-OS: Risk Factor Control Before Orthopedic Surgery (clinicaltrials.gov) - Dec 6, 2017
P4, N=198, Terminated, Sponsor: New York University School of Medicine
Initiation date: Nov 2017 --> Feb 2018 Trial primary completion date: Dec 2017 --> May 2017
- | lisinopril / Generic mfg.
Trial primary completion date: Lisinopril in Reducing Shortness of Breath Caused by Radiation Therapy in Patients With Lung Cancer (clinicaltrials.gov) - Dec 4, 2017
P=N/A, N=50, Active, not recruiting, Sponsor: Mayo Clinic
Trial primary completion date: Dec 2017 --> May 2017 Trial primary completion date: Dec 2017 --> Jul 2018
- | lisinopril / Generic mfg.
Journal: Incidence, Severity, and Outcomes of AKI Associated with Dual Renin-Angiotensin System Blockade. (Pubmed Central) - Dec 3, 2017
Trial primary completion date: Dec 2017 --> Jul 2018 Dual renin-angiotensin system blockade was associated with an increased risk of AKI compared with monotherapy, but AKI in the setting of monotherapy was associated with lower rates of recovery of kidney function, higher mortality, and higher risk of progression of kidney disease.
- lisinopril / Generic mfg.
Trial primary completion date: Endpoint Calibration for a Phase 2 Study of Lisinopril in Multiple Sclerosis (clinicaltrials.gov) - Oct 12, 2017
P2a, N=20, Recruiting, Sponsor: Transparency Life Sciences
Dual renin-angiotensin system blockade was associated with an increased risk of AKI compared with monotherapy, but AKI in the setting of monotherapy was associated with lower rates of recovery of kidney function, higher mortality, and higher risk of progression of kidney disease. Trial primary completion date: Mar 2017 --> Jun 2018
- | candesartan cilexetil / Generic mfg., lisinopril / Generic mfg.
Enrollment closed, Enrollment change, Trial primary completion date: CALIBREX: CAndesartan vs LIsinopril Effects on the BRain (clinicaltrials.gov) - Oct 4, 2017
P3, N=168, Active, not recruiting, Sponsor: Ihab M. Hajjar
Trial primary completion date: Mar 2017 --> Jun 2018 Recruiting --> Active, not recruiting | N=140 --> 168 | Trial primary completion date: Dec 2017 --> Nov 2018
- | Phase classification: COACH: Reducing Total Cardiovascular Risk in an Urban Community (clinicaltrials.gov) - Sep 15, 2017
P4, N=525, Completed, Sponsor: Johns Hopkins University
Recruiting --> Active, not recruiting | N=140 --> 168 | Trial primary completion date: Dec 2017 --> Nov 2018 Phase classification: P=N/A --> P4
- | lisinopril / Generic mfg.
Journal: Heterogeneity in Early Responses in ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial). (Pubmed Central) - Aug 26, 2017
Compared with those randomized to chlorthalidone, participants randomized to amlodipine (odds ratio, 1.20; 95% confidence interval [CI], 1.10-1.31), lisinopril (odds ratio, 1.88; 95% CI, 1.73-2.03), and doxazosin (odds ratio, 1.65; 95% CI, 1.52-1.78) had higher adjusted odds ratios associated with being a nonimmediate responder (versus immediate responder)...The SBP response trajectories provided superior discrimination for predicting downstream adverse cardiovascular events than classification based on difference in SBP between the first 2 measurements, SBP at 6 months, and average SBP during the first 6 months. Our findings demonstrate heterogeneity in response to antihypertensive therapies and show that chlorthalidone is associated with more favorable initial response than the other medications.
- || lisinopril / Generic mfg., carvedilol controlled-release / Generic mfg.
Enrollment change: Evaluation of Potential for Orthostatic Hypotension in Elderly Hypertensives (clinicaltrials.gov) - Aug 9, 2017
P1, N=62, Completed, Sponsor: GlaxoSmithKline
Our findings demonstrate heterogeneity in response to antihypertensive therapies and show that chlorthalidone is associated with more favorable initial response than the other medications. N=40 --> 62
- | lisinopril / Generic mfg.
New P2 trial: Optimal Management of HIV Infected Adults at Risk for Kidney Complications in Nigeria (clinicaltrials.gov) - Jun 27, 2017
P2, N=200, Not yet recruiting, Sponsor: Vanderbilt University Medical Center
- | lercanidipine / Generic mfg., furosemide / Generic mfg., lisinopril / Generic mfg.
New P4 trial: Effect of RAS Blockers on CKD Progression in Elderly Patients With Non Proteinuric Nephropathies (PROERCAN01) (clinicaltrials.gov) - Jun 22, 2017
P4, N=106, Recruiting, Sponsor: Hospital General Universitario Gregorio Mara
- | lisinopril / Generic mfg.
Journal: Effect of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) on Conduction System Disease. (Pubmed Central) - Jun 19, 2017
P3
Incident conduction system disease is significantly reduced by lisinopril therapy and is independently associated with multiple clinical factors. Further studies are warranted to determine whether pharmacologic treatment affects conduction abnormality outcomes, including pacemaker implantation.
- | lisinopril / Generic mfg.
Journal: Combined Hydration and Antibiotics with Lisinopril to Mitigate Acute and Delayed High-dose Radiation Injuries to Multiple Organs. (Pubmed Central) - Jun 2, 2017
Furthermore, lisinopril was an effective mitigator in the presence of the growth factor G-CSF (100 μg kg d from days 1-14), which is FDA-approved for use in a radionuclear event. In summary, by combining lisinopril (FDA-approved for other indications) with hydration and antibiotics, acute and delayed radiation injuries in multiple organs were mitigated.
- | Trial primary completion date: The Use of Ambulatory Blood Pressure Monitors to Assess Angiotensin Converting Enzyme Inhibitors (clinicaltrials.gov) - May 25, 2017
P1, N=20, Recruiting, Sponsor: Memorial Health University Medical Center
In summary, by combining lisinopril (FDA-approved for other indications) with hydration and antibiotics, acute and delayed radiation injuries in multiple organs were mitigated. Trial primary completion date: Apr 2016 --> Apr 2018
- | atenolol / Generic mfg., lisinopril / Generic mfg.
Trial primary completion date: Genetic Mechanisms in Human Hypertension Renin-angiotensin-aldosterone System (RAAS) Inhibition Study (clinicaltrials.gov) - May 18, 2017
P=N/A, N=100, Active, not recruiting, Sponsor: Brigham and Women's Hospital
Trial primary completion date: Apr 2016 --> Apr 2018 Trial primary completion date: Mar 2017 --> Mar 2018
- | lisinopril / Generic mfg.
Enrollment change, Trial termination: Effect of Angiotensin Converting Enzyme Inhibitor, Lisinopril, on Renal Blood Flow and Its Correlation With Proteinuria Reduction in Subjects With Type 2 Diabetes and Kidney Disease (clinicaltrials.gov) - May 12, 2017
P=N/A, N=6, Terminated, Sponsor: University of Virginia
Trial primary completion date: Mar 2017 --> Mar 2018 N=54 --> 6 | Recruiting --> Terminated; Slow Recruitment
- | lisinopril / Generic mfg.
Journal: Treatment Resistant Hypertension and Outcomes based on Randomized Treatment Group in ALLHAT. (Pubmed Central) - May 12, 2017
P3
In this study, which titrated medications to a goal, participants assigned to chlorthalidone were less likely to develop treatment-resistant hypertension. However, prognoses in those with treatment-resistant hypertension were similar across treatment groups.
- |||| Tryvio (aprocitentan) / J&J
Trial completion: Dose-finding Study With ACT-132577 (Aprocitentan) in Participants With Essential Hypertension (clinicaltrials.gov) - May 10, 2017
P2, N=1000, Completed, Sponsor: Actelion
However, prognoses in those with treatment-resistant hypertension were similar across treatment groups. Active, not recruiting --> Completed
- | hydrochlorothiazide / Generic mfg., lisinopril / Generic mfg.
Trial completion: Series of N-of-1 Crossover Trials of Antihypertensive Therapy in Adolescents With Essential Hypertension (clinicaltrials.gov) - May 5, 2017
P=N/A, N=42, Completed, Sponsor: The University of Texas Health Science Center, Houston
Active, not recruiting --> Completed Enrolling by invitation --> Completed
- | Trial completion, Surgery: Chronic Angiotensin Converting Enzyme Inhibitors in Intermediate Risk Surgery (clinicaltrials.gov) - May 2, 2017
P4, N=291, Completed, Sponsor: University of Nebraska
Enrolling by invitation --> Completed Enrolling by invitation --> Completed
- | Trial initiation date: HYGIA: Prognostic Value of the Circadian Pattern of Ambulatory Blood Pressure for Multiple Risk Assessment (clinicaltrials.gov) - Mar 27, 2017
P4, N=18000, Recruiting, Sponsor: University of Vigo
Enrolling by invitation --> Completed Initiation date: Jan 2008 --> Sep 2008
- | lisinopril / Generic mfg.
Trial primary completion date: Lisinopril in Reducing Shortness of Breath Caused by Radiation Therapy in Patients With Lung Cancer (clinicaltrials.gov) - Mar 22, 2017
P=N/A, N=50, Active, not recruiting, Sponsor: Mayo Clinic
Initiation date: Jan 2008 --> Sep 2008 Trial primary completion date: Dec 2016 --> Dec 2017
- | lisinopril / Generic mfg.
Trial completion, Trial primary completion date: The Renin-Angiotensin-Aldosterone System and Parathyroid Hormone Control: The RAAS-PARC Study (clinicaltrials.gov) - Mar 21, 2017
P=N/A, N=41, Completed, Sponsor: Brigham and Women's Hospital
Trial primary completion date: Dec 2016 --> Dec 2017 Active, not recruiting --> Completed | Trial primary completion date: Jun 2017 --> Aug 2016
- ||| Tryvio (aprocitentan) / J&J
Enrollment closed: Dose-finding Study With ACT-132577 (Aprocitentan) in Participants With Essential Hypertension (clinicaltrials.gov) - Jan 30, 2017
P2, N=1000, Active, not recruiting, Sponsor: Actelion
Active, not recruiting --> Completed | Trial primary completion date: Jun 2017 --> Aug 2016 Recruiting --> Active, not recruiting
- lisinopril / Generic mfg.
Trial primary completion date: The Renin-Angiotensin-Aldosterone System and Parathyroid Hormone Control: The RAAS-PARC Study (clinicaltrials.gov) - Dec 27, 2016
P=N/A, N=41, Active, not recruiting, Sponsor: Brigham and Women's Hospital
Recruiting --> Active, not recruiting Trial primary completion date: Dec 2016 --> Jun 2017
- | carvedilol / Generic mfg., metoprolol succinate / Generic mfg.
Trial termination: COREG MR Versus TOPROL-XL On Reduction Of Microalbuminuria In Patients With Hypertension And Microalbuminuria (clinicaltrials.gov) - Oct 25, 2016
P3, N=1220, Terminated, Sponsor: GlaxoSmithKline
Trial primary completion date: Dec 2016 --> Jun 2017 Completed --> Terminated
- lisinopril / Generic mfg.
Phase classification, Trial primary completion date: Endpoint Calibration for a Phase 2 Study of Lisinopril in Multiple Sclerosis (clinicaltrials.gov) - Oct 25, 2016
P2a, N=20, Recruiting, Sponsor: Transparency Life Sciences
Completed --> Terminated Phase classification: P2 --> P2a | Trial primary completion date: Nov 2015 --> Mar 2017
- || Tryvio (aprocitentan) / J&J
Trial primary completion date: Dose-finding Study With ACT-132577 (Aprocitentan) in Participants With Essential Hypertension (clinicaltrials.gov) - Oct 13, 2016
P2, N=1000, Recruiting, Sponsor: Actelion
Phase classification: P2 --> P2a | Trial primary completion date: Nov 2015 --> Mar 2017 Trial primary completion date: Dec 2016 --> Apr 2017
- || Tryvio (aprocitentan) / J&J
Trial primary completion date: Dose-finding Study With ACT-132577 (Aprocitentan) in Participants With Essential Hypertension (clinicaltrials.gov) - Sep 26, 2016
P2, N=1000, Recruiting, Sponsor: Actelion
Trial primary completion date: Dec 2016 --> Apr 2017 Trial primary completion date: Sep 2016 --> Dec 2016
- Humira (adalimumab) / AbbVie
Enrollment change: Novel Therapies for Resistant FSGS (FONTII): Phase II Clinical Trial (clinicaltrials.gov) - Jul 12, 2016
P2, N=32, Completed, Sponsor: New York University School of Medicine
Trial primary completion date: Sep 2016 --> Dec 2016 N=23 --> 32
- | Bystolic (nebivolol) / Menarini, AbbVie
New P4 trial: NT-proBNP Selected Prevention of Cardiac Events in Diabetic Patients (clinicaltrials.gov) - Jun 29, 2016
P4, N=2400, Recruiting, Sponsor: Martin Huelsmann
- atorvastatin / Generic mfg., lisinopril / Generic mfg.
Enrollment change, Trial termination, Surgery: OPTMIZE-OS: Risk Factor Control Before Orthopedic Surgery (clinicaltrials.gov) - Jun 11, 2016
P4, N=198, Terminated, Sponsor: New York University School of Medicine
N=23 --> 32 N=550 --> 198 | Recruiting --> Terminated; Low recruitment / DSMB approval to halt recruitment
- ||| Tryvio (aprocitentan) / J&J
Enrollment change: Dose-finding Study With ACT-132577 (Aprocitentan) in Participants With Essential Hypertension (clinicaltrials.gov) - Jun 9, 2016
P2, N=1000, Recruiting, Sponsor: Actelion
N=550 --> 198 | Recruiting --> Terminated; Low recruitment / DSMB approval to halt recruitment N=540 --> 1000
- lisinopril / Generic mfg.
Enrollment closed, Enrollment change: The Renin-Angiotensin-Aldosterone System and Parathyroid Hormone Control: The RAAS-PARC Study (clinicaltrials.gov) - Jun 2, 2016
P=N/A, N=41, Active, not recruiting, Sponsor: Brigham and Women's Hospital
N=540 --> 1000 Recruiting --> Active, not recruiting | N=30 --> 41
- Trial primary completion date, Surgery: Chronic Angiotensin Converting Enzyme Inhibitors in Intermediate Risk Surgery (clinicaltrials.gov) - May 25, 2016
P4, N=300, Enrolling by invitation, Sponsor: University of Nebraska
Recruiting --> Active, not recruiting | N=30 --> 41 Trial primary completion date: Apr 2016 --> Nov 2016
- lisinopril / Generic mfg.
Enrollment open: ACE-inhibitors in Extracapillary Glomerulonephritis (clinicaltrials.gov) - May 19, 2016
P2, N=22, Recruiting, Sponsor: Monia Lorini
Trial primary completion date: Apr 2016 --> Nov 2016 Not yet recruiting --> Recruiting
- | candesartan cilexetil / Generic mfg., lisinopril / Generic mfg.
New P4 trial: PHYSIC: The Precision Hypertension Care Study (clinicaltrials.gov) - May 18, 2016
P4, N=300, Not yet recruiting, Sponsor: Uppsala University
- hydrochlorothiazide / Generic mfg., lisinopril / Generic mfg.
Trial primary completion date: Series of N-of-1 Crossover Trials of Antihypertensive Therapy in Adolescents With Essential Hypertension (clinicaltrials.gov) - May 12, 2016
P=N/A, N=50, Enrolling by invitation, Sponsor: The University of Texas Health Science Center, Houston
Not yet recruiting --> Recruiting Trial primary completion date: Feb 2016 --> Jul 2016
- | New P4 trial: REMAP-CAP: Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia (clinicaltrials.gov) - Apr 13, 2016
P4, N=4000, Recruiting, Sponsor: UMC Utrecht
- atorvastatin / Generic mfg., lisinopril / Generic mfg.
Trial primary completion date, Surgery: OPTMIZE-OS: Risk Factor Control Before Orthopedic Surgery (clinicaltrials.gov) - Mar 30, 2016
P4, N=550, Recruiting, Sponsor: New York University School of Medicine
Trial primary completion date: Feb 2016 --> Jul 2016 Trial primary completion date: Jan 2016 --> Dec 2017
- | exenatide DUROS subcutaneous delivery system (ITCA 650) / i20 Therap
Trial completion: Study of the Effects of ITCA 650 on Gastric Emptying and Interaction of ITCA 650 on 4 Commonly Studied Drugs (clinicaltrials.gov) - Mar 22, 2016
P1, N=33, Completed, Sponsor: Intarcia Therapeutics
Trial primary completion date: Jan 2016 --> Dec 2017 Recruiting --> Completed
- | Hygroton (chlortalidone) / Alliance, NN1213 / Novo Nordisk
Trial completion: Genetics of Hypertension Associated Treatments (GenHAT) (clinicaltrials.gov) - Feb 27, 2016
P=N/A, N=0, Completed, Sponsor: University of Minnesota - Clinical and Translational Science Institute
Recruiting --> Completed No longer recruiting --> Completed
- |||| Tryvio (aprocitentan) / J&J
Enrollment open: Dose-finding Study With ACT-132577 (Aprocitentan) in Participants With Essential Hypertension (clinicaltrials.gov) - Feb 24, 2016
P2, N=540, Recruiting, Sponsor: Actelion
No longer recruiting --> Completed Not yet recruiting --> Recruiting
- lisinopril / Generic mfg.
New P2 trial: ACE-inhibitors in Extracapillary Glomerulonephritis (clinicaltrials.gov) - Feb 16, 2016
P2, N=22, Not yet recruiting, Sponsor: Monia Lorini
- | lisinopril / Generic mfg.
Enrollment open, Trial primary completion date: Clinical Trial of Coenzyme Q10 and Lisinopril in Muscular Dystrophies (clinicaltrials.gov) - Feb 3, 2016
P2/3, N=120, Enrolling by invitation, Sponsor: Cooperative International Neuromuscular Research Group
Not yet recruiting --> Recruiting Active, not recruiting --> Enrolling by invitation | Trial primary completion date: Dec 2016 --> Dec 2017